Patient journey from screening to CAR T-cell infusion for JULIET and... | Download Scientific Diagram
New CAR-T Data, Other Lymphoma Therapy Insights - Pharmacy Practice News
YESCARTA® (axicabtagene ciloleucel) Now Approved Treatment | HCP Site
ZUMA-7 Data Underscore Potential of CAR T-cell Therapy as Second-Line Standard in Relapsed/Refractory LBCL
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | Nature Medicine
ZUMA-7 - Capsule Summary Slidesets - Lymphomas and CLL - 2021 ASH Annual Meeting - Oncology - Clinical Care Options
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma | Business Wire
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma - ScienceDirect
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma | Business Wire
CAR T Cells: Second-Line Treatment Option for NHL? - NCI
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial - The Lancet Oncology
YESCARTA® (axicabtagene ciloleucel) Now Approved Treatment | HCP Site
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials - Westin - 2021 - American Journal of Hematology -
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma | BioSpace
Clinical Review Results - Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report - NCBI Bookshelf
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
Axi-cel vs SoC for R/R LBCL: ZUMA-7 primary analysis
Rapid Readout: ZUMA‑7: Axicabtagene Ciloleucel versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B‐Cell Lymphoma
CAR-T 'highly cost-effective' as second-line treatment for large B-cell lymphoma
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
Dr. Leslie on the Methods of the ZUMA-7 Trial in Relapsed/Refractory LBCL
Miguel Perales M.D. on Twitter: "#ASH21 Plenary - ZUMA-7 results: Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma #CARTcells https://t.co/embhPt2mkJ" / Twitter
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
EFS improvement with axi-cel CAR-T a 'breakthrough' in second-line treatment of DLBCL
